	US 12,233,083 B2
	Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
Robert Shalwitz, Bexley, OH (US); and Anna Kotsakis Ruehlmann, Cincinnati, OH (US)
Assigned to Invirsa, Inc., Columbus, OH (US)
Filed by Invirsa, Inc., Columbus, OH (US)
Filed on Sep. 11, 2023, as Appl. No. 18/244,693.
Application 18/244,693 is a continuation of application No. 17/171,548, filed on Feb. 9, 2021, granted, now 11,793,826.
Application 17/171,548 is a continuation of application No. 16/364,760, filed on Mar. 26, 2019, granted, now 10,946,034, issued on Mar. 16, 2021.
Claims priority of provisional application 62/693,021, filed on Jul. 2, 2018.
Claims priority of provisional application 62/648,585, filed on Mar. 27, 2018.
Prior Publication US 2023/0414647 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7076 (2006.01); A61K 9/00 (2006.01); A61K 31/7056 (2006.01); A61K 47/02 (2006.01); A61P 11/00 (2006.01); A61P 31/12 (2006.01); A61P 31/14 (2006.01); A61P 31/22 (2006.01)

CPC A61K 31/7076 (2013.01) [A61K 9/00 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/7056 (2013.01); A61K 47/02 (2013.01); A61P 11/00 (2018.01); A61P 31/12 (2018.01); A61P 31/14 (2018.01); A61P 31/22 (2018.01)]

34 Claims

1. A method of increasing the activity of Pax6 in a patient in need thereof, comprising administering to the patient an effective amount of ADPR, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopologue, or polymorph thereof.